Skip to content

Oruka Therapeutics, Inc.: current accounts payable

Oruka Therapeutics current accounts payable: $362.0 thousand at 2023-12-31, up 8.4% on the year. 14 values since 2010 from SEC filings. In original units.

All Oruka Therapeutics, Inc. financial histories

At a glance

Oruka Therapeutics reported current accounts payable of $362.0 thousand at 2023-12-31, up 8.4% from $334.0 thousand a year earlier. From 2010 to 2023 it fell at a compound 0.5% a year, from $388.0 thousand to $362.0 thousand. Across the last five reported years it ranged from $334.0 thousand (2022-12-31) to $1.77 million (2020-12-31). That was 1.0% of total assets ($37.9 million) at the same date.

Computed from the values in the table below, in USD; each links to the filing it came from.

What this measure means

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Exact concept: us-gaap:AccountsPayableCurrent. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2010-12-31 to 2023-12-31. The SEC response was captured on 2026-09-20.

This selected history ends more than two years before capture. Do not treat its final value as a current balance or current annual result. More recent filings may use another accounting tag; inspect the filings before drawing conclusions about the company.

Selected filing history

Current accounts payable in original reported units, latest-filed observation per period
Period startPeriod endValueUnitFiledSource filing
-2023-12-31362,000USD2024-02-0110-K · 0000950170-24-009809 SEC
-2022-12-31334,000USD2024-02-0110-K · 0000950170-24-009809 SEC
-2021-12-311,117,000USD2023-02-2410-K · 0000950170-23-004379 SEC
-2020-12-311,773,000USD2022-03-1410-K · 0001564590-22-010075 SEC
-2019-12-31418,000USD2021-03-1810-K · 0001564590-21-014148 SEC
-2018-12-31230,000USD2020-02-1810-K · 0001564590-20-005032 SEC
-2017-12-31622,000USD2019-02-2710-K · 0001564590-19-004882 SEC
-2016-12-311,205,000USD2018-03-2210-K · 0001564590-18-006566 SEC
-2015-12-31364,000USD2017-03-2110-K · 0001564590-17-004897 SEC
-2014-12-31795,000USD2016-03-1710-K · 0001564590-16-014989 SEC
-2013-12-31597,000USD2015-03-1910-K · 0001564590-15-001840 SEC
-2012-12-3165,000USD2014-03-2010-K · 0001564590-14-000934 SEC
-2011-12-31260,000USD2013-03-2110-K · 0001193125-13-119763 SEC
-2010-12-31388,000USD2012-03-2710-K · 0001193125-12-134451 SEC

Related Oruka Therapeutics, Inc. histories

All 45 Oruka Therapeutics histories

Inspect the source

Entity
Oruka Therapeutics, Inc. / CIK 0000907654
Captured
SEC response SHA-256
3e23b48bd43d48690cc2da8767bd994ea7ae37e724c61a9cefa6f2950dc21518

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

The MCP server is free and MIT-licensed: npx -y canli-mcp. If these records help your research, a star on GitHub helps other researchers find them.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000907654.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))